Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Biosimilars and Follow-On Biologics: World Market 2012-2022
Management Report
Published: June 2012
Pages: 213
Tables: For full details, please email deborahf@cmsinfo.com
From: GBP 1699.00 Buy Now!
Research from: pharmaceuticalmarketresearch
Sector: Prescription Medicines
What are the commercial prospects for biosimilar drugs? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.
This study investigates biosimilars (follow-on biologics). It lets you assess forecasted sales at world market, therapeutic submarket and national level to 2022.
Our investigation gives you business research and analysis with sales forecasts and opinion.
You discover forecasting of six submarkets to 2022, finding potential biosimilar revenues and comparisons with the overall biologics market at category level:
• Monoclonal antibodies (MAbs) and fusion proteins
• Insulin
• Interferons
• Erythropoietins
• G-CSF agents
• Growth hormones.
The new report gives you coverage of regulatory affairs too - FDA, EMA and others - assessing trends and outlooks for biosimilar drugs.
What will happen next? Our study shows you how biopharmaceutical competition will intensify. The R&D pipeline for follow-on biological drugs is strong and promising. Also, improved drug delivery will be important from 2012. You see how and why.
Patent expiry will erode blockbuster revenues in biopharma, creating many opportunities for biosimilars and related follow-on biologics. More than 20 blockbuster biologics will lose patent protection in the US by 2022.
High demand for more-affordable biological drugs will stimulate the market. We show you sales potentials there. You also see driving and restraining forces in that emerging industry.
What are biopharma companies doing? Our study discusses Sandoz, Teva, Dr. Reddy's, Wockhardt and others, evaluating prospects of the industry and market. You discover where leading companies are heading from 2012.
Many commercial opportunities for biosimilars and related products exist, with high revenues possible to 2022. Product launches will change the market. Our report shows and explains.
You can investigate biosimilar drugs now, discovering revenue potentials and other trends.
Revenue forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussion of R&D activities. You receive 80 tables, 67 charts and four research interviews.
Ten ways Biosimilars and Follow-On Biologics: World Market 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover market forecasting to 2022 for the US, Japan, the EU5 countries, China, India and South Korea
• Assess leading companies, discovering their activities and outlooks
• Explore approval pathways and regulatory guidelines for the US, the EU, Japan, China, India and South Korea
• Review R&D and product approvals, seeing pipelines and portfolios
• Find out when patents will expire on reference products
• See possible launch times for biosimilars, with discussions of potential
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey, seeing interviews with external authorities.
There, you find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
Companies Listed
3SBio
Abbott Laboratories
Actavis
Active Biotech
Agence française de sécurité sanitaire des produits de santé (AFSSAPS) [France]
Alexion Pharmaceuticals
Allozyne
Amgen
Apotex
Aprogen
AstraZeneca
Avesthagen
AxiCorp
Baxter International
Bayer
Beijing Shuanglu Medicine Co
Bioceuticals Arzneimittel (a subsidiary of Stada)
Biocon
Biogen Idec
BioGeneriX (a subsidiary of ratiopharm)
Biopartners
Biopharmaceuticals and Herbal Medicines Bureau [South Korea]
Bio-Technology General
Biotechnology Regulatory Authority of India (BRAI)
Bioton
BioXpress Therapeutics
Boehringer Ingelheim
BresaGen (now part of Hospira)
Bristol-Myers Squibb (BMS)
Cardiovascular and Renal Drugs Advisory Committee [US]
CCL Pharmaceuticals
cell pharm (a subsidiary of Stada)
Cell Therapeutics
Celltrion
Celltrion Healthcare (a subsidiary of Celltrion)
Centres of Medicare and Medicaid Services (CMS) [US]
Chiron (now part of Novartis)
CinnaGen
Committee for Medicinal Products for Human Use (CHMP) [EU]
Compass Biotechnologies (formerly Cyplasin Biomedical)
Congressional Budget Office (CBO) [US]
Covance
CT Arzneimittel
Department of Biotechnology (DBT) [India]
Diabetology
Dong-A Pharmaceuticals
Dr. Reddy's Laboratories
Eden Biodesign (a subsidiary of Watson Pharmaceuticals)
Egis Pharmaceuticals
Eisai
Elan
Eli Lilly
European Generic Medicines Association (EGA)
European Medicines Agency (EMA)
Feron
Ferring Pharmaceuticals
Finox
Food and Drug Administration (FDA) [US]
Food and Drug Law Institute (FDLI) [US]
Fraunhofer Institute [Germany]
Fuji Pharma
Fujifilm
Fujifilm Pharma (a subsidiary of Fujifilm)
Gedeon Richter
Genentech (now part of Roche)
GeneScience
Genetic Engineering Approval Council (GEAC) [India]
Genhelix
Genzyme (now part of Sanofi)
Getz Pharma
Gilead Sciences
GlycoFi (now part of Merck & Co)
GSK
HanAll BioPharma
Hanwha Chemical
Hemopharm
Hexal (a subsidiary of Novartis)
Hikma Pharmaceuticals
Hospira
Hospira Japan (a division of Hospira)
Hualida Biotech
Human Genome Sciences
Inhibitex
Insmed
Intas Biopharmaceuticals
Isu Abxis
Itero Biopharmaceuticals
JCR Pharmaceuticals
Johnson & Johnson (J&J)
Kissei Pharmaceutical
Korean Food and Drug Administration (KFDA)
Kwizda Pharma
Kyowa Hakko Kirin
LG
LG Life Sciences (a division of LG)
Lonza
Marvel Life Sciences
Medice
Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
MedImmune
Medtronic
Merck & Co.
Merck BioManufacturing Network (now part of Fujifilm)
Merck BioVentures (a division of Merck & Co)
Merck KGaA
Minapharm Pharmaceuticals
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Mochida Pharmaceutical
Momenta Pharmaceuticals
Mylan
National Health Service (NHS) [UK]
National Institute for Biological Standards and Control (NIBSC) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institute for the Control of Pharmaceutical and Biologic Products [China]
Nichi-Iko Pharmaceutical
Nippon Kayaku
Nobel Ilac
Novartis
Novo Nordisk
Nuron Biotech
Oncologic Drug Advisory Committee (ODAC) [US]
Owen Mumford
Parexel International
Pfenex
Pfizer
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmasset (a subsidiary of Gilead)
PlantForm
Prometheus Labs
Qilu Pharmaceutical
Quintiles
ratiopharm (now part of Teva)
RBC Capital Markets
Recombinant DNA Advisory Committee (RDAC) [India]
Reliance GeneMedix (a subsidiary of Reliance Life Sciences)
Reliance Group
Reliance Life Sciences (a division of Reliance Group)
Rentschler Biotechnologie
Review Committee on Genetic Manipulation (RCGM) [India]
Roche
Safety Syringes
Samsung
Samsung Bioepis (joint venture between Samsung BioLogics and Biogen Idec)
Samsung BioLogics (joint venture between Samsung and Quintiles)
Sandoz (part of Novartis)
Sanofi
Sawai Pharmaceutical
SciGen
Seattle Genetics
Shanghai Celgen Bio-Pharmaceutical
Shantha Biotechnics (now part of Sanofi)
Sheffield Bio-Science
Spectrum Pharmaceuticals
Stada Arzneimittel
State Food and Drug Administration (SFDA) [China]
Teva Pharmaceutical Industries
Teva-Kowa Pharma (a subsidiary of Teva)
Therapeutic Goods Administration (TGA) [Australia]
Toyota Tsusho
UCB
Watson Pharmaceuticals
Wockhardt
World Health Organization (WHO)
Wyeth (now part of Pfizer)
Zydus Cadila